# Kesimpta (ofatumumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ofatumumab

> The next catalyst for Kesimpta (ofatumumab), sponsored by NOVARTIS AG (NVS), is its topline data readout, Sep to Dec 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Kesimpta (ofatumumab) |
| Codes | OMB157 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | Multiple Sclerosis (MS), [Multiple Sclerosis](https://sec-api.dev/indications/multiple-sclerosis), [Relapsing Multiple Sclerosis](https://sec-api.dev/indications/relapsing-multiple-sclerosis) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### August 20, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125326 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20200820, review_priority PRIORITY; sponsor_name NOVARTIS; product KESIMPTA (OFATUMUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125326%22

### November 4, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04788615 (Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04788615

### March 25, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Multiple Sclerosis (MS).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04926818 (Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04926818

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03650114 (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03650114

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsing Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03650114 (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03650114

## Same indication

- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)
- [Imu-838 tablets](https://sec-api.dev/pdufa/imu-838) (IMUX)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [MRNA-1195](https://sec-api.dev/pdufa/mrna-1195) (MRNA)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Remibrutinib oral treatment](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) (NVS)
- [Aubagio (teriflunomide)](https://sec-api.dev/pdufa/teriflunomide) (SNY)
- [Tolebrutinib](https://sec-api.dev/pdufa/tolebrutinib) (SNY)
- [BRIUMVI® (ublituximab)](https://sec-api.dev/pdufa/ublituximab) (TGTX)

Calendar months: [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ofatumumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Kesimpta (ofatumumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ofatumumab

```bibtex
@misc{secapidev_pdufa_ofatumumab_20261116,
  title        = {Kesimpta (ofatumumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ofatumumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ofatumumab_20261116","title":"Kesimpta (ofatumumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ofatumumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
